Muscle deoxygenation in aerobic and anaerobic exercise.

S. Nioka,D. Moser,G. Lech,M. Evengelisti,T. Verde,B. Chance,S. Kuno

DOI: https://doi.org/10.1007/978-1-4615-4863-8_8

Advances in experimental medicine and biology

Abstract:

What problem does this paper attempt to address?

SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing glycolysis and modulating macrophage polarization

Xia-fang Lin,Xiao-na Cui,Jin Yang,Ya-fei Jiang,Tian-jiao Wei,Li Xia,Xin-yue Liao,Fei Li,Dan-dan Wang,Jian Li,Qi Wu,De-shan Yin,Yun-yi Le,Kun Yang,Rui Wei,Tian-pei Hong

DOI: https://doi.org/10.1038/s41401-024-01389-3

IF: 7.169

2024-09-19

Acta Pharmacologica Sinica

Abstract:Sodium-glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i) is a novel class of anti-diabetic drug, which has displayed a promising benefit for non-alcoholic fatty liver disease (NAFLD). In this study, we investigated the protective effects of SGLT2i against NAFLD and the underlying mechanisms. The db/db mice and western diet-induced NAFLD mice were treated with dapagliflozin (1 mg·kg −1 ·d −1 , i.g.) or canagliflozin (10 mg·kg −1 ·d −1 , i.g.) for 8 weeks. We showed that the SGLT2i significantly improved NAFLD-associated metabolic indexes, and attenuated hepatic steatosis and fibrosis. Notably, SGLT2i reduced the levels of pro-inflammatory cytokines and chemokines, downregulated M1 macrophage marker expression and upregulated M2 macrophage marker expression in liver tissues. In cultured mouse bone marrow-derived macrophages and human peripheral blood mononuclear cell-derived macrophages, the SGLT2i (10, 20 and 40 μmol/L) significantly promoted macrophage polarization from M1 to M2 phenotype. RNA sequencing, Seahorse analysis and liquid chromatography-tandem mass spectrometry analysis revealed that the SGLT2i suppressed glycolysis and triggered metabolic reprogramming in macrophages. By using genetic manipulation and pharmacological inhibition, we identified that the SGLT2i targeted PFKFB3, a key enzyme of glycolysis, to modulate the macrophage polarization of M1 to M2 phenotype. Using a co-culture of macrophages with hepatocytes, we demonstrated that the SGLT2i inhibited lipogenesis in hepatocytes via crosstalk with macrophages. In conclusion, this study highlights a potential therapeutic application for repurposing SGLT2i and identifying a potential target PFKFB3 for NAFLD treatment.

pharmacology & pharmacy,chemistry, multidisciplinary
Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways

Nami Lee,Yu Jung Heo,Sung-E Choi,Ja Young Jeon,Seung Jin Han,Dae Jung Kim,Yup Kang,Kwan Woo Lee,Hae Jin Kim

DOI: https://doi.org/10.1155/2021/9944880

IF: 4.4929

2021-06-02

Journal of Immunology Research

Abstract:Background. Sodium-glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase-4 (DPP-4) inhibitors are glucose-lowering drugs whose anti-inflammatory properties have recently become useful in tackling metabolic syndromes in chronic inflammatory diseases, including diabetes and obesity. We investigated whether empagliflozin (SGLT2 inhibitor) and gemigliptin (DPP-4 inhibitor) improve inflammatory responses in macrophages, identified signalling pathways responsible for these effects, and studied whether the effects can be augmented with dual empagliflozin and gemigliptin therapy. Methods. RAW 264.7 macrophages were first stimulated with lipopolysaccharide (LPS), then cotreated with empagliflozin, gemigliptin, or empagliflozin plus gemigliptin. We conducted quantitative RT-PCR (qRT-PCR) to determine the most effective anti-inflammatory doses without cytotoxicity. We performed ELISA and qRT-PCR for inflammatory cytokines and chemokines and flow cytometry for CD80, the M1 macrophage surface marker, to evaluate the anti-inflammatory effects of empagliflozin and gemigliptin. NF-κB, MAPK, and JAK2/STAT signalling pathways were examined via Western blotting to elucidate the molecular mechanisms of anti-inflammation. Results. LPS-stimulated CD80+ M1 macrophages were suppressed by coincubation with empagliflozin, gemigliptin, and empagliflozin plus gemigliptin, respectively. Empagliflozin and gemigliptin (individually and combined) inhibited prostaglandin E2 (PGE2) release and COX-2, iNOS gene expression in LPS-stimulated RAW 264.7 macrophages. These three treatments also attenuated the secretion and mRNA expression of proinflammatory cytokines, such as TNF-α, IL-1β, IL-6, and IFN-γ, and proinflammatory chemokines, such as CCL3, CCL4, CCL5, and CXCL10. All of them blocked NF-κB, JNK, and STAT1/3 phosphorylation through IKKα/β, MKK4/7, and JAK2 signalling. Conclusions. Our study demonstrated the anti-inflammatory effects of empagliflozin and gemigliptin via IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 pathway downregulation in macrophages. In all cases, combined empagliflozin and gemigliptin treatment showed greater anti-inflammatory properties.

immunology
Non-Lyn Src Family Kinases Activate SIRPα-SHP-1 to Inhibit PI3K-Akt2 and Dampen Proinflammatory Macrophage Polarization

Lei Shi,Zhen Bian,Koby Kidder,Hongwei Liang,Yuan Liu

DOI: https://doi.org/10.4049/jimmunol.2100266

2021-09-01

Abstract:Macrophage functional plasticity plays a central role in responding to proinflammatory stimuli. The molecular basis underlying the dynamic phenotypic activation of macrophages, however, remains incompletely understood. In this article, we report that SIRPα is a chief negative regulator of proinflammatory macrophage polarization. In response to TLR agonists, proinflammatory cytokines, or canonical M1 stimulation, Src family kinases (SFK) excluding Lyn phosphorylate SIRPα ITIMs, leading to the preferential recruitment and activation of SHP-1, but not SHP-2. Solely extracellular ligation of SIRPα by CD47 does not greatly induce phosphorylation of SIRPα ITIMs, but it enhances proinflammatory stimuli-induced SIRPα phosphorylation. Examination of downstream signaling elicited by IFN-γ and TLR3/4/9 agonists found that SIRPα-activated SHP-1 moderately represses STAT1, NF-κB, and MAPK signaling but markedly inhibits Akt2, resulting in dampened proinflammatory cytokine production and expression of Ag presentation machinery. Pharmacological inhibition of SHP-1 or deficiency of SIRPα conversely attenuates SIRPα-mediated inhibition and, as such, augments macrophage proinflammatory polarization that in turn exacerbates proinflammation in mouse models of type I diabetes and peritonitis. Our results reveal an SFK-SIRPα-SHP-1 mechanism that fine-tunes macrophage proinflammatory phenotypic activation via inhibition of PI3K-Akt2, which controls the transcription and translation of proinflammatory cytokines, Ag presentation machinery, and other cellular programs.
Targeting Inflammatory Signaling Pathways with SGLT2 Inhibitors: Insights into Cardiovascular Health and Cardiac Cell Improvement

Fatmah R. Alsereidi,Zenith Khashim,Hezlin Marzook,Anamika Gupta,Ahmed M. Shaaban,Mahmoud M. Ramadan,Mohamed A. Saleh

DOI: https://doi.org/10.1016/j.cpcardiol.2024.102524

IF: 16.464

2024-03-17

Current Problems in Cardiology

Abstract:Sodium-glucose cotransporter 2 (SGLT2) inhibitors have attracted significant attention for their broader therapeutic impact beyond simply controlling blood sugar levels, particularly in their ability to influence inflammatory pathways. This review delves into the anti-inflammatory properties of SGLT2 inhibitors, with a specific focus on canagliflozin, empagliflozin, and dapagliflozin. One of the key mechanisms through which SGLT2 inhibitors exert their anti-inflammatory effects is by activating AMP-activated protein kinase (AMPK), a crucial regulator of both cellular energy balance and inflammation. Activation of AMPK by these inhibitors leads to the suppression of pro-inflammatory pathways and a decrease in inflammatory mediators. Notably, SGLT2 inhibitors have demonstrated the ability to inhibit the release of cytokines in an AMPK-dependent manner, underscoring their direct influence on inflammatory signaling. Beyond AMPK activation, SGLT2 inhibitors also modulate several other inflammatory pathways, including the NLRP3 inflammasome, expression of Toll-like receptor 4 (TLR-4), and activation of NF-κB (Nuclear factor kappa B). This multifaceted approach contributes to their efficacy in reducing inflammation and managing associated complications in conditions such as diabetes and cardiovascular disorders. Several human and animal studies provide support for the anti-inflammatory effects of SGLT2 inhibitors, demonstrating protective effects on various cardiac cells. Additionally, these inhibitors exhibit direct anti-inflammatory effects by modulating immune cells. Overall, SGLT2 inhibitors emerge as promising therapeutic agents for targeting inflammation in a range of pathological conditions. Further research, particularly focusing on the molecular-level pathways of inflammation, is necessary to fully understand their mechanisms of action and optimize their therapeutic potential in inflammatory diseases.

cardiac & cardiovascular systems
Unilateral EEG activation during sleep in the Cape fur seal, Arctocehalus pusillus

O. Lyamin,I. S. Chetyrbok

DOI: https://doi.org/10.1016/0304-3940(92)90279-G

IF: 3.197

1992-08-31

Neuroscience Letters

Abstract:
SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease

So Ra Kim,Sang-Guk Lee,Soo Hyun Kim,Jin Hee Kim,Eunhye Choi,Wonhee Cho,John Hoon Rim,Inhwa Hwang,Chan Joo Lee,Minyoung Lee,Chang-Myung Oh,Justin Y. Jeon,Heon Yung Gee,Jeong-Ho Kim,Byung-Wan Lee,Eun Seok Kang,Bong-Soo Cha,Myung-Shik Lee,Je-Wook Yu,Jin Won Cho,Jung-Sun Kim,Yong-ho Lee

DOI: https://doi.org/10.1038/s41467-020-15983-6

IF: 16.6

2020-05-01

Nature Communications

Abstract:Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events in humans with type 2 diabetes (T2D); however, the underlying mechanism remains unclear. Activation of the NLR family, pyrin domain-containing 3 (NLRP3) inflammasome and subsequent interleukin (IL)-1β release induces atherosclerosis and heart failure. Here we show the effect of SGLT2 inhibitor empagliflozin on NLRP3 inflammasome activity. Patients with T2D and high cardiovascular risk receive SGLT2 inhibitor or sulfonylurea for 30 days, with NLRP3 inflammasome activation analyzed in macrophages. While the SGLT2 inhibitor’s glucose-lowering capacity is similar to sulfonylurea, it shows a greater reduction in IL-1β secretion compared to sulfonylurea accompanied by increased serum β-hydroxybutyrate (BHB) and decreased serum insulin. Ex vivo experiments with macrophages verify the inhibitory effects of high BHB and low insulin levels on NLRP3 inflammasome activation. In conclusion, SGLT2 inhibitor attenuates NLRP3 inflammasome activation, which might help to explain its cardioprotective effects.

multidisciplinary sciences
Macrophage polarization: an effective approach to targeted therapy of inflammatory bowel disease

Yaoyao Du,Lan Rong,Yuanhua Cong,Lan Shen,Ning Zhang,Bing Wang

DOI: https://doi.org/10.1080/14728222.2021.1901079

IF: 6.797

2021-03-17

Expert Opinion on Therapeutic Targets

Abstract:Introduction: Inflammatory bowel disease (IBD) is a systemic disease with immune abnormalities that can affect the entire digestive tract. A high percentage of patients with IBD are unresponsive to current pharmacological agents, hence the need exists for novel therapeutic approaches. There is compelling evidence that macrophage polarization plays a key role in the remission of IBD patients and that it could open up future treatment options for patients.Areas covered: This paper highlights the crucial role of macrophage polarization in IBD. The authors shed light on the phenotype and function of macrophages and potential drug targets for polarization regulation. Existing approaches for regulating macrophage polarization are discussed and potential solutions for safety concerns are considered. We performed a literature search on the IBD and macrophage polarization mainly published in PubMed January 2010–July 2020.Expert opinion: Evidence indicates that there are fewer M2 macrophages and a high proportion of M1 macrophages in the intestinal tissues of individuals who are non- responsive to treatment. Regulating macrophage polarization is a potential novel targeted option for IBD treatment. Improved mechanistic insights are required to uncover more precise and effective targets for skewing macrophages into a proper phenotype.

pharmacology & pharmacy
Lactate-driven macrophage polarization in the inflammatory microenvironment alleviates intestinal inflammation

Hai-Cun Zhou,Wen-Wen Yu,Xin-Yan Yan,Xiao-Qin Liang,Xiu-Feng Ma,Jian-Ping Long,Xiao-Yan Du,Hong-Yan Mao,Hong-Bin Liu

DOI: https://doi.org/10.3389/fimmu.2022.1013686

IF: 7.3

2022-10-18

Frontiers in Immunology

Abstract:Background Lactate has long been considered an intermediate by-product of glucose metabolism. However, in recent years, accumulating evidence reveals that lactate has unique biological activities. In previous studies, lactate signaling was shown to inhibit inflammation. Furthermore, in vitro experiments have shown that lactate can promote the transformation of pro-inflammatory macrophages into anti-inflammatory macrophages. However, no in vivo studies have shown whether lactate can alleviate inflammation. Methods RAW 264.7 macrophages were stimulated by LPS to induce an M1 phenotype, and cultured with low and high concentrations of lactate. The cells were then observed for phenotypic transformations and expression of inflammatory mediators and surface markers. The expression of inflammatory factors was also analyzed in the cell-free supernatant fraction. Further, a mouse model of DSS-induced colitis was established and treated with lactate. Colonic tissue injury was monitored by histopathological examinations. Results The in vitro experiments showed that lactate promoted the transformation of activated macrophages to M2 phenotype and decreased the expression of TLR4-mediated NF-κB signaling proteins and inflammatory factors. In the DSS-induced colitis mouse model, lactate promoted the phenotypic transformation of macrophages in colonic tissue, reduced inflammation and organ damage, inhibited the activation of TLR4/NF-κB signaling pathway, decreased the serum levels of pro-inflammatory factors, increased the expression of anti-inflammatory factors, promoted the repair of the intestinal mucosal barrier and reduced the severity of colitis. Conclusions Lactate inhibits the TLR/NF-κB signaling pathway and the production of pro-inflammatory factors by promoting polarization of macrophages. In addition, lactate promotesthe repair of the intestinal mucosal barrier and protects intestinal tissue in inflammation. Furthermore, lactate is relatively safe. Therefore, lactate is a promising and effective drug for treating inflammation through immunometabolism regulation.

immunology
GI inflammation Increases Sodium-Glucose Cotransporter Sglt1

Jiyoung Park,In-Seung Lee,Kang-Hoon Kim,Yumi Kim,Eun-Jin An,Hyeung-Jin Jang

DOI: https://doi.org/10.3390/ijms20102537

IF: 5.6

2019-05-23

International Journal of Molecular Sciences

Abstract:A correlation between gastrointestinal (GI) inflammation and gut hormones has reported that inflammatory stimuli including bacterial endotoxins, lipopolysaccharides (LPS), TNFα, IL-1β, and IL-6 induces high levels of incretin hormone leading to glucose dysregulation. Although incretin hormones are immediately secreted in response to environmental stimuli, such as nutrients, cytokines, and LPS, but studies of glucose-induced incretin secretion in an inflamed state are limited. We hypothesized that GI inflammatory conditions induce over-stimulated incretin secretion via an increase of glucose-sensing receptors. To confirm our hypothesis, we observed the alteration of glucose-induced incretin secretion and glucose-sensing receptors in a GI inflammatory mouse model, and we treated a conditioned media (Mφ 30%) containing inflammatory cytokines in intestinal epithelium cells and enteroendocrine L-like NCI-H716 cells. In GI-inflamed mice, we observed that over-stimulated incretin secretion and insulin release in response to glucose and sodium glucose cotransporter (Sglt1) was increased. Incubation with Mφ 30% increases Sglt1 and induces glucose-induced GLP-1 secretion with increasing intracellular calcium influx. Phloridzin, an sglt1 inhibitor, inhibits glucose-induced GLP-1 secretion, ERK activation, and calcium influx. These findings suggest that the abnormalities of incretin secretion leading to metabolic disturbances in GI inflammatory disease by an increase of Sglt1.
S1PR2/RhoA/ROCK1 pathway promotes inflammatory bowel disease by inducing intestinal vascular endothelial barrier damage and M1 macrophage polarization

Xuewen Wang,Shuhua Chen,Hong Xiang,Xiaoyan Wang,Jie Xiao,Shaoli Zhao,Zhihao Shu,Jie Ouyang,Ziwei Liang,Minzi Deng,Xuejie Chen,Jing Zhang,Huiqin Liu,Qisheng Quan,Peng Gao,Jianing Fan,Alex F Chen,Hongwei Lu,Xuewen Wang,Shuhua Chen,Hong Xiang,Xiaoyan Wang,Jie Xiao,Shaoli Zhao,Zhihao Shu,Jie Ouyang,Ziwei Liang,Minzi Deng,Xuejie Chen,Jing Zhang,Huiqin Liu,Qisheng Quan,Peng Gao,Jianing Fan,Alex F Chen,Hongwei Lu

DOI: https://doi.org/10.1016/j.bcp.2022.115077

IF: 6.1

2022-07-01

Biochemical Pharmacology

Abstract:Vascular and immune dysfunctions are thought to be related to the pathogenesis of inflammatory bowel disease (IBD), but behind this, the exact mechanism of mucosal vascular endothelial barrier dysfunction and macrophage phenotypic transition is not fully understood. Here, we explored the mechanistic role of sphingosine 1-phosphate receptor 2 (S1PR2) and its downstream G protein RhoA/Rho kinase 1 (ROCK1) signaling pathway in the intestinal endothelial barrier damage and M1 macrophage polarization in IBD. We found that the expression of S1PR2 in intestinal mucosal vascular endothelial cells and macrophages of IBD patients and DSS-induced colitis mice as well as vascular endothelial cells and macrophages treated with LPS in vitro was significantly increased. Knocking down or pharmacologically inhibiting S1PR2 significantly downregulated the expression of RhoA and ROCK1 in vascular endothelial cells and macrophages. Furthermore, inhibition of S1PR2 and ROCK1 reversed the impaired vascular barrier function and M1 macrophage polarization in vivo and in vitro, while reducing ER stress in vascular endothelial cells and glycolysis in macrophages. In addition, inhibition of ER stress or glycolysis reversed LPS-induced impairment of vascular endothelial cell barrier function and M1 macrophage polarization. Collectively, our results indicate that the S1PR2/RhoA/ROCK1 signaling pathway may participate in the pathogenesis of IBD by regulating vascular endothelial barrier function and M1 macrophage polarization.

pharmacology & pharmacy
MALT1 inhibitors prevent the development of DSS-induced experimental colitis in mice via inhibiting NF-κB and NLRP3 inflammasome activation

Wen Liu,Wenjie Guo,Nan Hang,Yuanyuan Yang,Xuefeng Wu,Yan Shen,Jingsong Cao,Yang Sun,Qiang Xu

DOI: https://doi.org/10.18632/oncotarget.8867

2016-04-20

Oncotarget

Abstract:Mucosa-associated-lymphoid-tissue lymphoma-translocation gene 1 (MALT1), a paracaspase and essential regulator for nuclear factor kB (NF-κB) activation, plays an important role in innate and adaptive immunity. Suppression of MALT1 protease activity with small molecule inhibitors showed promising efficacies in subtypes of B cell lymphoma and improvement in experimental autoimmune encephalomyelitis model. However, whether MALT1 inhibitors could ameliorate colitis remains unclear. In the present study, we examined the pharmacological effect of two specific MALT1 inhibitors MI-2 and mepazine on the dextran sulfate sodium (DSS)-induced experimental colitis in mice, followed by mechanistic analysis on NF-κB and NLRP3 inflammasome activation. Treatment with MI-2 and mepazine dose-dependently attenuated symptoms of colitis in mice, evidenced by reduction in the elevated disease activity index, the shortening of colon length as well as the histopathologic improvement. Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF, IL-1β, IL-6, IL-18, IL-17A and IFN-γ, were markedly suppressed by MALT1 inhibitors. The underlying mechanisms for the protective effect of MALT1 inhibitors in DSS-induced colitis may be attributed to its inhibition on NF-κB and NLRP3 inflammasome activation in macrophages. The in vitro study showed that MALT1 inhibitors decreased production of IL-1β/IL-18 in phorbol myristate acetate-differentiated THP-1 cells and bone marrow derived macrophage via suppressing the activation of NF-κB and NLRP3 inflammasome. Taken together, our results demonstrated that inhibition of the protease activity of MALT1 might be a viable strategy to treat inflammatory bowel disease and the NLRP3 inflammasome and NF-κB activation are critical components in MALT1 signaling cascades in this disease model.
Myeloid-derived growth factor ameliorates dextran sodium sulfate-induced colitis by regulating macrophage polarization

Yang Yang,Conghui Zhao,Zi Yang,Conglin Du,Zhichao Chang,Xin Wen,Xiujuan Zhang,Yi Liu,Liang Hu,Zhenhua Gao

DOI: https://doi.org/10.1007/s00109-024-02447-3

Abstract:Inflammatory bowel disease (IBD) is characterized by inflammatory conditions in the gastrointestinal tract. According to reports, IBD prevalence is increasing globally, with heavy economic and physical burdens. Current IBD clinical treatment is limited to pharmacological methods; therefore, new strategies are needed. Myeloid-derived growth factor (MYDGF) secreted by bone marrow-derived mononuclear macrophages has beneficial effects in multiple inflammatory diseases. To this end, the present study aimed to establish an experimental IBD mouse model using dextran sulfate sodium in drinking water. MYDGF significantly alleviated DSS-induced colitis, suppressed lymphocyte infiltration, restored epithelial integrity in mice, and decreased apoptosis in the colon tissue. Moreover, the number of M1 macrophages was decreased and that of M2 macrophages was increased by the action of MYDGF. In MYDGF-treated mice, the NF-κB and MAPK pathways were partially inhibited. Our findings indicate that MYDGF could mitigate DSS-induced mice IBD by reducing inflammation and restoring epithelial integrity through regulation of intestinal macrophage polarization via NF-κB and MAPK pathway inhibition. KEY MESSAGES: MYDGF alleviated DSS-induced acute colitis. MYDGF maintains colon epithelial barrier integrity and relieves inflammation. MYDGF regulates colon macrophage polarization. MYDGF partially inhibited the activation of NF-κB and MAPK pathway.
SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney

Qingqing Ke,Caifeng Shi,Yunhui Lv,Lulu Wang,Jing Luo,Lei Jiang,Junwei Yang,Yang Zhou

DOI: https://doi.org/10.1096/fj.202100909rr

2021-12-17

The FASEB Journal

Abstract:Large clinical trials and real-world studies have demonstrated that the beneficial effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes regardless of the presence of diabetes. However, the mechanism remains obscure. Here, we analyze the anti-fibrotic and anti-inflammatory effects of dapagliflozin, a SGLT2 inhibitor, on renal alternations using the ischemia/reperfusion-induced fibrosis model. Transcriptome and metabolome analysis showed that the accumulation of tricarboxylic acid (TCA) cycle metabolites and upregulation of inflammation in fibrosis renal cortical tissue were mitigated by dapagliflozin treatment. Moreover, dapagliflozin markedly relieved the activation of mammalian target of rapamycin and hypoxia inducible factor-1α signaling and restored tubular cell-preferred fatty acid oxidation. Notably, NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome activation was strikingly blocked by dapagliflozin. We further demonstrated that the immunomodulatory metabolite itaconate derived from the TCA cycle was significantly boosted as a result of decreased isocitrate dehydrogenase 2 and increased immune-responsive gene 1 and mitochondrial citrate carrier in dapagliflozin-treated mice, which contributed to the inhibitory effect of dapagliflozin on NLRP3 inflammasome activation. Furthermore, administration of cell-permeable itaconate surrogate prevented activation of NLRP3 inflammasome and protected kidney against fibrosis development. Our results identify a novel mechanism coupling metabolism and inflammation for kidney benefits of SGLT2 inhibition in progressive chronic kidney disease.
Inhibition of METTL3 in macrophages provides protection against intestinal inflammation

Huilong Yin,Zhuan Ju,Xiang Zhang,Wenjie Zuo,Yuhang Yang,Minhua Zheng,Xiaofang Zhang,Yuning Liu,Yingran Peng,Ying Xing,Angang Yang,Rui Zhang

DOI: https://doi.org/10.1038/s41423-024-01156-8

2024-04-23

Cellular and Molecular Immunology

Abstract:Inflammatory bowel disease (IBD) is prevalent, and no satisfactory therapeutic options are available because the mechanisms underlying its development are poorly understood. In this study, we discovered that increased expression of methyltransferase-like 3 (METTL3) in macrophages was correlated with the development of colitis and that depletion of METTL3 in macrophages protected mice against dextran sodium sulfate (DSS)-induced colitis. Mechanistic characterization indicated that METTL3 depletion increased the YTHDF3-mediated expression of phosphoglycolate phosphatase (PGP), which resulted in glucose metabolism reprogramming and the suppression of CD4+ T helper 1 (Th1) cell differentiation. Further analysis revealed that glucose metabolism contributed to the ability of METTL3 depletion to ameliorate colitis symptoms. In addition, we developed two potent small molecule METTL3 inhibitors, namely, F039-0002 and 7460-0250, that strongly ameliorated DSS-induced colitis. Overall, our study suggests that METTL3 plays crucial roles in the progression of colitis and highlights the potential of targeting METTL3 to attenuate intestinal inflammation for the treatment of colitis.

immunology
Gastrodin Attenuates Lipopolysaccharide-Induced Inflammatory Response and Migration via the Notch-1 Signaling Pathway in Activated Microglia

Yue-Yi Yao,Run Li,Yan-Ji Guo,Yu Zhao,Jia-Zhi Guo,Qing-Long Ai,Lian-Mei Zhong,Di Lu

DOI: https://doi.org/10.1007/s12017-021-08671-1

Abstract:Microglia-mediated neuroinflammation is known to play a pivotal role in the pathogenesis of different neurological diseases. Gastrodin, a phenolic glucoside, has been reported to exert anti-inflammatory effects in activated microglia challenged with lipopolysaccharide (LPS); however, the underlying mechanism has remained obscure. The present study aimed to ascertain if Gastrodin would regulate the Notch signaling pathway involved in microglia activation. We show here that LPS increased the expression of various members of the Notch-1 pathway, including intracellular Notch receptor domain (NICD), recombining binding protein suppressor of hairless (RBP-Jκ) and transcription factor hairy and enhancer of split-1 (Hes-1) in microglia in postnatal rat brain and in BV-2 microglia. Remarkably, Gastrodin was found to markedly attenuate the expression of the above various biomarkers both in vivo and in vitro. Moreover, increased phosphorylation level of ERK, JNK and P38 induced by LPS was attenuated with pretreatment of Notch-1 signaling inhibitor, N-[N-(3,5-difluorophenacetyl)-1-alany1-Sphenyglycinet-butylester (DAPT) as well as Gastrodin. Gastrodin mimicked the effects of DAPT by inhibiting the LPS-induced expression of IL-1β, IL-6, IL-23, TNF-α and NO. Moreover, lentivirus transfection mediated NICD overexpression inhibited the anti-inflammatory effects of Gastrodin. Furthermore, the activation of Notch-1 signaling promoted microglia migration and Gastrodin could inhibit the migration of activated BV-2 microglia by regulating the Notch-1 signaling pathway. In light of the above, our results indicate that Notch-1 signaling pathway is involved in the anti-inflammatory effects of Gastrodin against LPS-induced microglia activation. These findings provide a new biological target of Gastrodin for the treatment of neuroinflammatory disorders.
Potential negative regulation of damage-recognition proteins in cisplatin-resistant HeLa cells in response to DNA damage.

C. Chao

DOI: https://doi.org/10.1016/0165-7992(91)90046-7

1991-10-01

Mutation Research

Abstract:
A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah.

R. Siegler,A. Pavia,R. Christofferson,Milligan Mk

DOI: https://doi.org/10.1542/peds.94.1.35

1994-07-01

PEDIATRICS

Abstract:OBJECTIVE To determine epidemiologic features, trends in frequency, and predictors of clinical outcome of postdiarrheal hemolytic uremic syndrome (HUS) in Utah. DESIGN A 20-year population-based study of HUS with a review of the HUS registry, hospital records, transplant registry, and a survey of pediatricians and pediatric nephrologists to ensure completeness of ascertainment. POPULATION All Utah residents under 18 years of age with HUS occurring after a diarrheal prodrome between 1971 and 1990. OUTCOME MEASURES Incidence of HUS, severity, complications, and long-term sequelae. RESULTS There were 157 cases during 20 years; 140 (89%) occurred after a diarrheal prodrome. The mean annual incidence was 1.42/100,000 children (range 0.2 to 3.4/100,000 children/year). Periods of high incidence occurred; however, there was no overall sustained increase in incidence. Escherichia coli O157:H7 was isolated from the stool of 62% of children who had specimens submitted. There were no differences between the first and second decade in the proportion with diarrheal prodrome, bloody diarrhea, most abnormal laboratory values, hospital course, or outcome. However, admission laboratory abnormalities were more severe during the first decade suggesting a delay in diagnosis. Age < 2 years, anuria before admission, and higher white blood cell counts on admission predicted severe disease. Bad outcome (death, end-stage renal disease, or stroke) occurred in 11%; 5% died. Chronic renal sequelae, usually mild, were found on follow-up (median 6.5 years) in 51% of survivors. CONCLUSIONS HUS has been an important clinical and public health problem in Utah for 20 years. The consistency of the clinical and epidemiologic features over 2 decades suggests that a common etiologic agent has accounted for most cases of HUS in this region since 1971.
N-methyladenosine-modified PIAS1 promotes microglia polarization to M1 by regulating PPARγ SUMOylation in Inflammatory Bowel Disease-associated hyperalgesia

Yulin Huang,Rui Xu,Bailing Hou,Yu’e Sun,Yanting Mao,Yan Yang,Xiaoping Gu,Wei Zhang,Zhengliang Ma

DOI: https://doi.org/10.21203/rs.3.rs-3306886/v1

2023-01-01

Abstract:Abstract Background and Aims: Large number of nociceptive signals produced by intestinal inflammation are transmitted to the spinal dorsal horn, leading to microglia polarization, which is of great significance in mediating central sensitization. Emerging evidence indicate that m6A modification regulates a dynamic macrophage polarization. However, it remains unsolved to link polarization of microglia regulated by m6a modification to inflammatory bowel disease (IBD) associated hyperalgesia. Methods IBD-induced hyperalgesia was assessed by paw withdrawal mechanical threshold in a murine colitis model induced by dextran sulphate sodium (DSS). MeRIP sequence was performed on the LPS-treated primary microglia. The biological role and mechanism of m6A modified PIAS1 in microglia polarization and central sensitization were determined in vitro and in vivo. Results The level of m6A RNA was significantly increased in the spinal dorsal cord of colitis mice, accompanied by microglia polarization to M1-proinflammatory phenotype, and METTL3 was the main regulator involved in the abundant m6A RNA modification. Moreover, MeRIP sequence identified PIAS1 acts anti-inflammatory function though promoting PPARγ SUMOylation in regulating microglia polarization. Mechanistically, the m6A reader YTHDF2 directly recognized and bound to the m6A site on PIAS1 mRNA and reduced PIAS1 mRNA stability. Overexpression YTHDF2 decreased PIAS1 mRNA level and promoted the polarization to M1-phenotype in vitro. Finally, reduced m6A modification by specific downregulation METTL3 in microglia of the spinal dorsal horn contributes to alleviate IBD-associated hyperalgesia. Conclusions The mRNA stabilization of m6A-modified PIAS1-mediated PPARγ SUMOylation as the underlying mechanism through which METTL3 preserved M1-phenotype microglia contributes to IBD-associated hyperalgesia.
GLP‐1 receptor agonists alleviate colonic inflammation by modulating intestinal microbiota and the function of group 3 innate lymphoid cells

Hanxiao Sun,Jie Shu,Jupei Tang,Yue Li,Jinxin Qiu,Zhaoyun Ding,Binbin Xuan,Minghui Chen,Chenxin Gan,Jinpiao Lin,Ju Qiu,Huiming Sheng,Chuanxin Wang

DOI: https://doi.org/10.1111/imm.13784

2024-03-29

Immunology

Abstract:Our findings show that Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) exert a therapeutic effect on colitis possibly by regulating the microbiota‐DMS‐IL‐22+ILC3 axis, highlighting the potential beneficial role of GLP‐1 RAs in inflammatory intestinal disorders with diabetes complications. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), which are drugs used for treating type 2 diabetes, have been reported to exert anti‐inflammatory effects on inflammatory bowel disease (IBD), the mechanism of which remains elusive. Here, we report that GLP‐1RAs ameliorate dextran sulfate sodium (DSS)‐induced colitis in both wild‐type and T/B‐cell‐deficient mice through modulating group 3 innate lymphoid cells (ILC3s), a subset of innate lymphoid cells that regulate intestinal immunity. GLP‐1RAs promote IL‐22 production by ILC3, and the protective effect of GLP‐1RAs on DSS‐induced colitis was abrogated in ILC3‐deficient RORgtgfp/gfp mice. Furthermore, the treatment effect of GLP‐RAs on colitis, as well as the generation of IL‐22‐producing ILC3s by GLP‐RAs, is dependent on the gut microbiota. GLP‐1RAs increase the abundance of Firmicutes and Proteobacteria in the gut, particularly beneficial bacteria such as Lactobacillus reuteri, and decrease the abundance of enteropathogenic Staphylococcus bacteria. The untargeted gas chromatography (GC)/liquid chromatography (LC)‐mass spectrometry (MS) of faecal metabolites further revealed enrichment of N,N‐dimethylsphingosine (DMS), an endogenous metabolite derived from sphingosine, in the GLP‐1RA‐treated group. Strikingly, DMS ameliorates colitis while promoting intestinal IL‐22‐producing ILC3s. Taken together, our findings show that GLP‐1RAs exert a therapeutic effect on colitis possibly by regulating the microbiota‐DMS‐IL‐22+ILC3 axis, highlighting the potential beneficial role of GLP‐RAs in inflammatory intestinal disorders with diabetes complications.

immunology
Lycium barbarum polysaccharide alleviates dextran sodium sulfate-induced inflammatory bowel disease by regulating M1/M2 macrophage polarization via the STAT1 and STAT6 pathways

Juan Wang,Huiying Gao,Yuan Xie,Peng Wang,Yu Li,Junli Zhao,Chunlin Wang,Xin Ma,Yuwen Wang,Qinwen Mao,Haibin Xia

DOI: https://doi.org/10.3389/fphar.2023.1044576

IF: 5.6

2023-04-19

Frontiers in Pharmacology

Abstract:Disruption of colonic homeostasis caused by aberrant M1/M2 macrophage polarization contributes to the development of inflammatory bowel disease (IBD). Lycium barbarum polysaccharide (LBP) is the primary active constituent of traditional Chinese herbal Lycium barbarum L. , which has been widely demonstrated to have important functions in regulating immune activity and anti-inflammatory. Thus, LBP may protect against IBD. To test this hypothesis, the DSS-induced colitis model was established in mice, then the mice were treated with LBP. The results indicated that LBP attenuated the weight loss, colon shortening, disease activity index (DAI), and histopathological scores of colon tissues in colitis mice, suggesting that LBP could protect against IBD. Besides, LBP decreased the number of M1 macrophages and the protein level of Nitric oxide synthase 2(NOS2) as a marker of M1 macrophages and enhanced the number of M2 macrophages and the protein level of Arginase 1(Arg-1) as a marker of M2 macrophages in colon tissues from mice with colitis, suggesting that LBP may protect against IBD by regulating macrophage polarization. Next, the mechanistic studies in RAW264.7 cells showed that LBP inhibited M1-like phenotype by inhibiting the phosphorylation of STAT1, and promoted M2-like phenotype by promoting the phosphorylation of STAT6. Finally, immunofluorescence double-staining results of colon tissues showed that LBP regulated STAT1 and STAT6 pathways in vivo . The results in the study demonstrated that LBP could protect against IBD by regulating macrophage polarization through the STAT1 and STAT6 pathways.

pharmacology & pharmacy

Muscle deoxygenation in aerobic and anaerobic exercise.

SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing glycolysis and modulating macrophage polarization

Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways

Non-Lyn Src Family Kinases Activate SIRPα-SHP-1 to Inhibit PI3K-Akt2 and Dampen Proinflammatory Macrophage Polarization

Targeting Inflammatory Signaling Pathways with SGLT2 Inhibitors: Insights into Cardiovascular Health and Cardiac Cell Improvement

Unilateral EEG activation during sleep in the Cape fur seal, Arctocehalus pusillus

SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease

Macrophage polarization: an effective approach to targeted therapy of inflammatory bowel disease

Lactate-driven macrophage polarization in the inflammatory microenvironment alleviates intestinal inflammation

GI inflammation Increases Sodium-Glucose Cotransporter Sglt1

S1PR2/RhoA/ROCK1 pathway promotes inflammatory bowel disease by inducing intestinal vascular endothelial barrier damage and M1 macrophage polarization

MALT1 inhibitors prevent the development of DSS-induced experimental colitis in mice via inhibiting NF-κB and NLRP3 inflammasome activation

Myeloid-derived growth factor ameliorates dextran sodium sulfate-induced colitis by regulating macrophage polarization

SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney

Inhibition of METTL3 in macrophages provides protection against intestinal inflammation

Gastrodin Attenuates Lipopolysaccharide-Induced Inflammatory Response and Migration via the Notch-1 Signaling Pathway in Activated Microglia

Potential negative regulation of damage-recognition proteins in cisplatin-resistant HeLa cells in response to DNA damage.

A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah.

N-methyladenosine-modified PIAS1 promotes microglia polarization to M1 by regulating PPARγ SUMOylation in Inflammatory Bowel Disease-associated hyperalgesia

GLP‐1 receptor agonists alleviate colonic inflammation by modulating intestinal microbiota and the function of group 3 innate lymphoid cells

Lycium barbarum polysaccharide alleviates dextran sodium sulfate-induced inflammatory bowel disease by regulating M1/M2 macrophage polarization via the STAT1 and STAT6 pathways